1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL STEM CELL THERAPY MARKET BY TYPE
5.1. Introduction
5.2. Allogenic
5.3. Autologous
6. GLOBAL STEM CELL THERAPY MARKET BY APPLICATION
6.1. Introduction
6.2. Musculoskeletal Disorder
6.3. Neurological Disorder
6.4. Cardiovascular Disease
6.5. Oncology
6.6. Others
7. GLOBAL STEM CELL THERAPY MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Specialty Clinics
7.4. Research & Academic Institute
7.5. Others
8. GLOBAL STEM CELL THERAPY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Vericel Corporation
10.2. Globus Medical Inc.
10.3. Athersys, Inc.
10.4. Bristol-Myers Squibb Company
10.5. Jcr Pharmaceuticals Co., Ltd.
10.6. Anterogen Co., Ltd.
10.7. Takeda Pharmaceutical Company Limited
10.8. Fate Therapeutics
10.9. Gilead Sciences, Inc.
10.10. Mesoblast Ltd
10.11. Pharmicell Inc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES